United States · Industrial & Consumer Products · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Calidi Biotherapeutics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -752.16% | 318.6% | 75.95% | 43.18% | 30.19% | 23.31% |
|---|---|---|---|---|---|---|
| Sector average | -213.05% | -30.99% | 76.25% | 96.15% | 83.7% | 17.59% |
| ROA | -172.8% | -333.43% | -618% | -618.21% | -619.07% | -622.8% |
| Total Assets | $8,857.00K | $3,257.00K | $3,257.00K | $3,257.00K | $3,257.00K | $3,257.00K |
| Net Income | -$19,906.00K | -$20,196.06K | -$20,128.20K | -$20,135.00K | -$20,163.22K | -$20,284.58K |